Complications of thalassemia major and their treatment

References

• Cao A, Galanello R. β-thalassemia. Genet. Med.12(2), 61–76 (2010).
   PubMed Web of Science ®Google Scholar
• Cooley TB, Lee P. A series of cases of splenomegaly in children with anemia and peculiar bone changes. Trans. Am. Pediatr.Soc.37, 29–34 (1925).
   Google Scholar
• Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu. Rev. Med.62, 347–360 (2011).
   PubMed Web of Science ®Google Scholar
• Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood102(7), 2670–2677 (2003).
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Cappellini MD, De Stefano P et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood107(9), 3733–3737 (2006).
   PubMed Web of Science ®Google Scholar
• Elalfy MS, Abdin IA, El Safy UR, Ibrahim AS, Ebeid FS, Salem DS. Cardiac events and cardiac T2* in Egyptian children and young adults with β-thalassemia major taking deferoxamine. Hematol. Oncol. Stem Cell Ther.3(4), 174–178 (2010).
   PubMedGoogle Scholar
• Glickstein H, El RB, Link G et al. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood108(9), 3195–3203 (2006).
   PubMed Web of Science ®Google Scholar
• Bosquet J, Navarro M, Robert G, Aye P, Michel FB. Rapid desensitisation for desferrioxamine anaphylactoid reaction. Lancet8, 2(8354), 859–860 (1983).
   Google Scholar
• Albera R, Pia F, Morra B et al. Hearing loss and desferrioxamine in homozygous β-thalassemia. Audiology27(4), 207–214 (1988).
   PubMed Web of Science ®Google Scholar
• Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JW. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br. J. Haematol.73(3), 403–409 (1989).
   PubMed Web of Science ®Google Scholar
• Arden GB, Wonke B, Kennedy C, Huehns ER. Ocular changes in patients undergoing long-term desferrioxamine treatment. Br. J. Ophthalmol.68(12), 873–877 (1984).
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, De Stefano P, Broglia AM. Visual loss in patient on high-dose subcutaneous desferrioxamine. Lancet1(8378), 681 (1984).
   PubMedGoogle Scholar
• De Virgiliis S, Congia M, Frau F et al. Deferoxamine-induced growth retardation in patients with thalassemia major. J. Pediatr.113(4), 661–669 (1988).
   PubMed Web of Science ®Google Scholar
• Gallant T, Freedman MH, Vellend H, Francombe WH. Yersinia sepsis in patients with iron overload treated with deferoxamine. N. Engl. J. Med.314(25), 1643 (1986).
   PubMed Web of Science ®Google Scholar
• Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br. J. Haematol.108(2), 305–312 (2000).
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Piga A et al. A Phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood107(9), 55–3462 (2006).
   Google Scholar
• Piga A, Longo F, Consolati A et al. Mortality and morbidity in thalassaemia with conventional treatment. Bone Marrow Transplant.19, 1–13 (1997).
   PubMed Web of Science ®Google Scholar
• Ladis V, Berdousi H, Palamidou F et al. Morbidity and mortality of iron intoxication in adult patients with thalassemia major, and effectiveness of chelation. Transfus. Sci.23(3), 255–256 (2000).
   PubMedGoogle Scholar
• Rund D, Rachmilewitz E. Thalassemia major 1995: older patients, new therapies. Blood Rev.9(1), 25–32 (1995).
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica89(10), 1187–1193 (2004).
   PubMed Web of Science ®Google Scholar
• Marsella M, Borgna-Pignatti C, Meloni A et al. Cardiac iron and cardiac disease in males and females with transfusion-dependent thalassemia major: a T2* MRI study. Haematologica96(4), 15–20 (2011).
   Google Scholar
• Walker JM, The heart in thalassaemia. Eur. Heart J.23(2), 102–105 (2002).
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Holden S, Davis B et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur. Heart J.22(23), 2171–2179 (2001).
   PubMed Web of Science ®Google Scholar
• Kirk P, Roughton M, Porter JB et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation120(20), 1961–1968 (2009).
   PubMed Web of Science ®Google Scholar
• Pepe A, Positano V, Capra M et al. Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassaemia major. Heart95(20), 1688–1693 (2009).
   PubMed Web of Science ®Google Scholar
• Kirk P, Carpenter JP, Tanner MA, Pennell DJ. Low prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson.13, 8 (2011).
   PubMedGoogle Scholar
• Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson.10, 42 (2008).
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Porter JB, Cappellini MD et al. Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica96(1), 48–54 (2011).
   PubMed Web of Science ®Google Scholar
• Wood JC, Kang BP, Thompson A et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood116(4), 537–543 (2010).
   PubMed Web of Science ®Google Scholar
• Tanner MA, Galanello R, Dessi C et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J. Cardiovasc. Magn. Reson.10, 12 (2008).
   PubMed Web of Science ®Google Scholar
• Lai ME, Grady RW, Vacquer S et al. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. Blood Cells Mol. Dis.45(2), 136–139 (2010).
   PubMed Web of Science ®Google Scholar
• Telfer PT, Warburton F, Christou S et al. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. Haematologica94(12), 1777–1778 (2009).
   PubMed Web of Science ®Google Scholar
• Ladis V, Chouliaras G, Berdoukas V et al. Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek unit. Eur. J. Haematol.85(4), 335–344 (2010).
   PubMed Web of Science ®Google Scholar
• Cogliandro T, Derchi G, Mancuso L et al. Society for the Study of Thalassemia and Hemoglobinopathies (SoSTE). Guideline recommendations for heart complications in thalassemia major. J. Cardiovasc. Med.9(5), 515–525 (2008).
   Google Scholar
• Mirmomen S, Alavian SM, Hajarizadeh B et al. Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infections in patients with β-thalassemia in Iran: a multicenter study. Arch. Iran Med.9(4), 319–323 (2006).
   PubMedGoogle Scholar
• Singh H, Pradhan M, Singh RL et al. High frequency of hepatitis B virus infection in patients with β-thalassemia receiving multiple transfusions. Vox Sang.84(4), 292–299 (2003).
   PubMed Web of Science ®Google Scholar
• Ramia S, Koussa S, Taher A et al. Hepatitis-C-virus genotypes and hepatitis-G-virus infection in Lebanese thalassaemics. Ann. Trop. Med. Parasitol.96(2), 197–202 (2002).
   PubMed Web of Science ®Google Scholar
• Prati D, Lin YH, De Mattei C et al. A prospective study on TT virus infection in transfusion-dependent patients with β-thalassemia. Blood93(5), 1502–1505 (1999).
   PubMed Web of Science ®Google Scholar
• Dodd RY. Current risk for transfusion transmitted infections. Curr. Opin. Hematol.14(6), 671–676 (2007).
   PubMed Web of Science ®Google Scholar
• Fraquelli M, Cassinerio E, Roghi A et al. Transient elastography in the assessment of liver fibrosis in adult thalassemia patients. Am. J. Hematol.85(8), 564–568 (2010).
   PubMed Web of Science ®Google Scholar
• Di Marco V, Bronte F, Cabibi D et al. Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE): lack of interference by iron deposition. Br. J. Haematol.148(3), 476–479 (2009).
   PubMed Web of Science ®Google Scholar
• Angelucci E, Muretto P, Nicolucci A et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood100(1), 17–21 (2002).
   PubMed Web of Science ®Google Scholar
• St Pierre TG, Clark PC, Chua-Anusorn W et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood105(2), 855–861 (2005).
   PubMed Web of Science ®Google Scholar
• Wood JC, Enriquez C, Ghugre N et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood106(4), 1460–1465 (2005).
   PubMed Web of Science ®Google Scholar
• Wood JC. Magnetic resonance imaging measurement of iron overload. Curr. Opin. Hematol.14(3), 183–190 (2007).
   PubMed Web of Science ®Google Scholar
• McCaughan GW, Omata M, Amarapurkar D et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J. Gastroenterol. Hepatol.22(5), 615–633 (2007).
   PubMed Web of Science ®Google Scholar
• Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J. Hepatol.22(6), 696–699 (1995).
   PubMed Web of Science ®Google Scholar
• Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C: the METAVIR Cooperative Study Group. Hepatology24(2), 289–293 (1996).
   PubMed Web of Science ®Google Scholar
• Perifanis V, Tziomalos K, Tsatra I et al. Prevalence and severity of liver disease in patients with β-thalassemia major: a single institution fifteen-year experience. Haematologica90(8), 1136–1138 (2005).
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Vergine G, Lombardo T et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br. J. Haematol.124(1), 114–117 (2004).
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J. Hepatol.50(2), 227–242 (2009).
   PubMed Web of Science ®Google Scholar
• Di Marco V, Capra M, Angelucci E et al. Italian Society for the Study of Thalassemia and Haemoglobinopathies; Italian Association for the Study of the Liver. Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood116(16), 2875–2883 (2010).
   PubMed Web of Science ®Google Scholar
• Harmatz P, Jonas MM, Kwiatkowski JL et al. Safety and efficacy of pegylated interferon α-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica93(8), 1247–1251 (2008).
   PubMed Web of Science ®Google Scholar
• Costin G, Kogut MD, Hyman CB, Ortega A. Endocrine abnormalities in thalassemia major. Am. J. Dis. Child.133(5), 497–502 (1979).
   PubMedGoogle Scholar
• Wood JC, Noetzl L, Hyderi A, Joukar M, Coates T, Mittelman S. Predicting pituitary iron and endocrine dysfunction. Ann. NY Acad. Sci.1202, 123–128 (2010).
   PubMed Web of Science ®Google Scholar
• Gamberini MR, De Sanctis V, Gilli G. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre. Ped. Endocrinol. Rev.6(Suppl. 1), 158–169 (2008).
   PubMedGoogle Scholar
• Italian Working Group on Endocrine Complications in Non-Endocrine Disease. Multicentre study on prevalence of endocrine complications in thalassemia major. Clin. Endocrinol.42(6), 581–586 (1995).
   PubMed Web of Science ®Google Scholar
• Shalitin S, Carmi D, Weintrob N et al. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients. Eur. J. Haematol.74(2), 93–100 (2005).
   PubMed Web of Science ®Google Scholar
• De Sanctis V, Roos M, Gasser T et al. Impact of long-term iron chelation therapy on growth and endocrine function in thalassaemia. J. Pediatr. Endocrinol. Metab.19(4), 417–480 (2006).
   Google Scholar
• Mowla A, Karimi M, Afrasiabi A, De Sanctis V. Prevalence of diabetes mellitus and impaired glucose tolerance in β-thalassemia patients with and without hepatitis C virus infection. Pediatr. Endocrinol. Rev.2(Suppl. 2), 282–284 (2004).
   PubMedGoogle Scholar
• Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of β-thalassemia major in North America. Blood104(1), 34–39 (2004).
   PubMed Web of Science ®Google Scholar
• Jensen CE, Tuck CM, Morris RW et al. Incidence of endocrine complications and clinical disease severity related to genotype analysis in patients with β-thalassemia. Eur. J. Haematol.59(2), 76–81 (1997).
   PubMed Web of Science ®Google Scholar
• Caruso-Nicoletti M, De Sanctis V, Cavallo L et al. Management of puberty for optimal auxological result in β-thalassaemia major. J. Pediatr. Endocrinol. Metab.14(Suppl. 2), 939–944 (2001).
   PubMed Web of Science ®Google Scholar
• Skordis N, Petrikkos L, Toumba M et al. Update on fertility in thalassaemia major. Pediatr. Endocrinol. Rev.2(Suppl. 2), 296–302 (2004).
   PubMedGoogle Scholar
• Jensen C, Abdel-Gadir A, Cox C, Tuck SM, Wonke B. Sperm counts and quality in β-thalassaemia major. Int. J. Androl.19(6), 362–364 (1996).
   PubMedGoogle Scholar
• Origa R, Piga A, Quarta G et al. Pregnancy and β-thalassemia: an Italian multicenter experience. Haematologica95(3), 376–381 (2010).
   PubMed Web of Science ®Google Scholar
• Zervas A, Katopodi A, Protonotariou A et al. Assessment of thyroid function in two hundred patients with β-thalassemia major. Thyroid12(2), 151–154 (2002).
   PubMed Web of Science ®Google Scholar
• Filosa A, Di Maio S, Aloj G, Acampora C. Longitudinal study on thyroid function in patients with thalassaemia major. J. Pediatr. Endocrinol. Metab.19(12), 1397–1404 (2006).
   PubMed Web of Science ®Google Scholar
• De Sanctis V, Tanas R, Gamberini MR, Sprocati M, Govoni MR, Marsella M. Exaggerated TSH response to TRH (‘sub-biochemical’ hypothyroidism) in prepubertal and adolescent thalassaemic patients with iron overload: prevalence and 20-year natural history. Ped. Endocrinol. Rev.6(Suppl. 1), 170–173 (2008).
   PubMedGoogle Scholar
• Sabato AR, De Sanctis V, Atti G, Capra L, Bagni B, Vullo C. Primary hypothyroidism and low T3 syndrome in thalassemia major. Arch. Dis. Child.58(2), 120–127 (1983).
   PubMed Web of Science ®Google Scholar
• Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br. J. Haematol.148(3), 466–475 (2010).
   PubMed Web of Science ®Google Scholar
• De Sanctis V, De Sanctis E, Ricchieri P, Gubellini E, Gilli G, Gamberini MR. Mild subclinical hypothyroidism in thalassaemia major: prevalence, multigated radionuclide test, clinical and laboratory long-term follow-up study. Pediatr. Endocrinol. Rev.6(Suppl. 1), 174–180 (2008).
   PubMedGoogle Scholar
• Mariotti S, Loviselli A, Murenu S et al. High prevalence of thyroid dysfunction in adult patients with β-thalassemia major submitted to amiodarone treatment. J. Endocrinol. Invest.22(1), 55–63 (1999).
   PubMed Web of Science ®Google Scholar
• De Sanctis V, Vullo C, Bagni B, Chiccoli L. Hypoparathyroidism in β-thalassemia major. Clinical and laboratory observations in 24 patients. Acta Haematol.88(2–3), 105–108 (1992).
   PubMed Web of Science ®Google Scholar
• Angelopoulos NG, Goula A, Rombopoulos G et al. Hypoparathyroidism in transfusion-dependent patients with β-thalassemia. J. Bone Miner. Metab.24(2), 138–145 (2006).
   PubMed Web of Science ®Google Scholar
• Karimi M, Rasekhi AR, Rasekh M, Nabavizadeh SA, Assadsangabi R, Amirhakimi GH. Hypoparathyroidism and intracerebral calcification in patients with β-thalassemia major. Eur. J. Radiol.70(3), 481–484 (2009).
   PubMed Web of Science ®Google Scholar
• Gamberini MR, Fortini M, De Sanctis V, Gilli G, Tetsa R. Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center. Ped. Endocrinol. Rev.2(Suppl. 2), 285–291 (2004).
   PubMedGoogle Scholar
• Incorvaia C, Parmeggiani F, Mingrone G, Sebastiani A, De Sanctis V. Prevalence of retinopathy in diabetic thalassaemic patients. J. Pediatr. Endocrinol. Metab.11(Suppl. 3), 879–883 (1998).
   PubMed Web of Science ®Google Scholar
• Merkel PA, Simonson DC, Amiel SA et al. Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. N. Engl. J. Med.318(13), 809–814 (1988).
   PubMed Web of Science ®Google Scholar
• Papakonstantinou O, Ladis V, Kostaridou S et al. The pancreas in β-thalassemia major: MR imaging features and correlation with iron stores and glucose disturbances. Eur. Radiol.17(6), 1535–1543 (2007).
   PubMed Web of Science ®Google Scholar
• Sougleri M, Labropoulou-Karatza C, Paraskevopoulou P, Fragopanagou H, Alexandrides T. Chronic hepatitis C virus infection without cirrhosis induces insulin resistance in patients with α-thalassaemia major. Eur. J. Gastroenterol. Hepatol.13(10), 1195–1199 (2001).
   PubMed Web of Science ®Google Scholar
• Pollack MS, Levine LS, Oberfield SE, Markenson AL. HLA-A, B, C, and DR antigen frequencies in relation to development of diabetes and variations in white cell antibody formation in highly transfused thalassemia patients. Transfusion22(4), 279–282 (1982).
   PubMed Web of Science ®Google Scholar
• Mangiagli A, Campisi S, De Sanctis V et al. Effects of acarbose in patients with β-thalassaemia major and abnormal glucose homeostasis. Pediatr. Endocrinol. Rev.2(Suppl. 2), 276–278 (2004).
   PubMedGoogle Scholar
• Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G, Tolis G. Effect of enhanced iron chelation therapy on glucose metabolism in patients with β-thalassaemia major. Br. J. Haematol.134(4), 438–444 (2006).
   PubMed Web of Science ®Google Scholar
• Kattamis C, Touliatos N, Haidas S, Matsaniotis N. Growth of children with thalassaemia: effect of different transfusion regimens. Arch. Dis. Child.45(242), 502–509 (1970).
   PubMed Web of Science ®Google Scholar
• De Sanctis V, Katz M, Vullo C, Bagni B, Ughi M, Wonke B. Effect of different treatment regimes on linear growth and final height in β-thalassaemia major. Clin. Endocrinol. (Oxf).40(6), 791–798 (1994).
   PubMed Web of Science ®Google Scholar
• De Sanctis V, Pinamonti A, Di Palma A et al. Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine. Eur. J. Pediatr.155(5), 368–372 (1996).
   PubMed Web of Science ®Google Scholar
• Saenger P, Schwartz E, Markenson AL et al. Depressed serum somatomedin activity in β-thalassemia. J. Pediatr.96(2), 214–218 (1980).
   PubMed Web of Science ®Google Scholar
• Cavallo L, Gurrado R, Gallo F, Zacchino C, De Mattia D, Tatò L. Growth deficiency in polytransfused β-thalassaemia patients is not growth hormone dependent. Clin. Endocrinol.46(6), 701–706 (1997).
   PubMed Web of Science ®Google Scholar
• Wu KH, Tsai FJ, Peng CT. Growth hormone (GH) deficiency in patients with β-thalassemia major and the efficacy of recombinant GH treatment. Ann. Hematol.82(10), 637–640 (2003).
   PubMed Web of Science ®Google Scholar
• Soliman AT, Khalafallah H, Ashour R. Growth and factors affecting it in thalassemia major. Hemoglobin33(Suppl. 1), S116–S126 (2009).
   PubMedGoogle Scholar
• Cavallo L, Gurrado R, Zecchino C et al. Short-term therapy with recombinant growth hormone in polytransfused thalassaemia major patients with growth deficiency. J. Pediatr. Endocrinol. Metab.11(Suppl. 3), 845–849 (1998).
   PubMed Web of Science ®Google Scholar
• La Rosa C, De Sanctis V, Mangiagli A et al. Growth hormone secretion in adult patients with thalassaemia. Clin. Endocrinol.62(6), 667–671 (2005).
   PubMed Web of Science ®Google Scholar
• Vidergor G, Goldfarb AW, Glaser B, Dresner-Pollak R. Growth hormone reserve in adult β thalassemia patients. Endocrine31(1), 33–37 (2007).
   PubMed Web of Science ®Google Scholar
• Poggi M, Pascucci C, Monti S et al. Prevalence of growth hormone deficiency in adult polytransfused β-thalassemia patients and correlation with transfusional and chelation parameters. J. Endocrinol. Invest.33(8), 534–538 (2010).
   PubMed Web of Science ®Google Scholar
• Sklar CA, Lew LQ, Yoon DJ, David R. Adrenal function in thalassemia major following long-term treatment with multiple transfusions and chelation therapy. Evidence for dissociation of cortisol and adrenal androgen secretion. Am. J. Dis. Child.141(3), 327–330 (1987).
   PubMedGoogle Scholar
• Srivatsa A, Marwaha RK, Muraldharan R, Trehan A. Assessment of adrenal endocrine function in Asian thalassemics. Indian Pediatr.42(1), 31–35 (2005).
   PubMed Web of Science ®Google Scholar
• Scacchi M, Danesi L, Cattaneo A et al. The pituitary–adrenal axis in adult thalassaemic patients. Eur. J. Endocrinol.162(1), 43–48 (2010).
   PubMed Web of Science ®Google Scholar
• Bornstein SR. Predisposing factors for adrenal insufficiency. N. Engl. J. Med.360(22), 2328–2339 (2009).
   PubMed Web of Science ®Google Scholar
• Vogiatzi MG, Macklin EA, Trachtenberg FL et al. Differences in the prevalence of growth, endocrine and vitamin D abnormalitues among the various thalassaemia syndromes in North America. Br. J. Haematol.146(5), 546–556 (2009).
   PubMed Web of Science ®Google Scholar
• Origa R, Fiumana E, Gamberini MR et al. Osteoporosis in β-thalassemia: clinical and genetic aspects. Ann. NY Acad. Sci.1054, 451–456 (2005).
   PubMed Web of Science ®Google Scholar
• Jensen CE, Tuck SM, Agnew JE et al. High prevalence of low bone mass in thalassaemia major. Br. J. Haematol.103(4), 911–915 (1998).
   PubMed Web of Science ®Google Scholar
• Morabito N, Gaudio A, Lasco A et al. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J. Bone Miner Res.19(5), 722–727 (2004).
   PubMed Web of Science ®Google Scholar
• Voskaridou E, Christoulas D, Antoniadou L, Terpos E. Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis. Acta Haematol.119(1), 40–44 (2008).
   PubMed Web of Science ®Google Scholar
• Holick MF. Vitamin D deficiency. N. Engl. J. Med.357(3), 266–281 (2007).
   PubMed Web of Science ®Google Scholar
• Jackson RD, LaCroix AZ, Gass M et al. Calcium plus vitamin D supplementation and the risk of fractures. N. Engl. J. Med.354(7), 669–683 (2006).
   PubMed Web of Science ®Google Scholar
• Jaipakdee S, Prasongwatana V, Premgamone A et al. The effects of potassium and magnesium supplementations on urinary risk factors of renal stone patients. J. Med. Assoc. Thai.87(3), 255–263 (2004).
   PubMedGoogle Scholar
• Vieth R, Cole DE. Teriparatide, osteoporosis, calcium, and vitamin D. N. Engl. J. Med.353(6), 634–635 (2005).
   PubMedGoogle Scholar
• Neuprez A, Hiligsmann M, Scholtissen S, Bruyere O, Reginster JY. Strontium ranelate: the first agent of a new therapeutic class in osteoporosis. Adv. Ther.25(12), 1235–1256 (2008).
   PubMed Web of Science ®Google Scholar
• Gelmi C, Borgna-Pignatti C, Franchin S, Tacchini M, Trimarchi F. Electroretinographic and visual-evoked potential abnormalities in patients with β-thalassemia major. Ophthalmologica196(1), 29–34 (1988).
   PubMed Web of Science ®Google Scholar
• Fabbri E, Forni GL, Guerrini G, Borgna-Pignatti C. Pseudoxanthoma-elasticum-like syndrome and thalassemia: an update. Dermatol. Online J.15(7), 7 (2009).
   PubMedGoogle Scholar
• Hu X, Plomp AS, van Soest S, Wijnholds J, de Jong PT, Bergen AA. Pseudoxanthoma elasticum: a clinical, histopathological, and molecular update. Surv. Ophthalmol.48(4), 424–438 (2003).
   PubMed Web of Science ®Google Scholar
• Hamlin N, Beck K, Bacchelli B, Cianciulli P, Pasquali-Ronchetti I, Le Saux O. Acquired pseudoxanthoma elasticum-like syndrome in β-thalassaemia patients. Br. J. Haematol.122, 852–854 (2003).
   PubMed Web of Science ®Google Scholar
• Farmakis D, Deftereos S, Giakoumis A, Polymeropoulos E, Aessopos A. Rupture of chordae tendineae in patients with β-thalassemia. Eur. J. Haematol.72(4), 296–298 (2004).
   PubMed Web of Science ®Google Scholar
• Farmakis D, Vesleme V, Papadogianni A, Tsaftaridis P, Kapralos P, Aessopos A. Aneurysmatic dilatation of ascending aorta in a patient with β-thalassemia and a pseudoxanthoma elasticum-like syndrome. Ann. Hematol.83(9), 596–599 (2004).
   PubMed Web of Science ®Google Scholar
• Cianciulli P, Sorrentino F, Maffei L et al. Cardiovascular involvement in thalassaemic patients with pseudoxanthoma elasticum-like skin lesions: a long-term follow-up study. Eur. J. Clin. Invest.32(9), 700–706 (2002).
   PubMed Web of Science ®Google Scholar
• Li Q, Larusso J, Grand-Pierre AE, Uitto J. Magnesium carbonate-containing phosphate binder prevents connective tissue mineralization in Abcc6-/- mice-potential for treatment of pseudoxanthoma elasticum. Clin. Transl. Sci.2(6), 398–404 (2009).
   PubMed Web of Science ®Google Scholar
• Borgna Pignatti C, Carnelli V, Caruso V et al. Thromboembolic events in β thalassemia major: an Italian multicenter study. Acta Haematol.99(2), 76–79 (1998).
   PubMed Web of Science ®Google Scholar
• Taher A, Isma’eel H, Mehio G et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb. Haemost.96(4), 488–491 (2006).
   PubMed Web of Science ®Google Scholar
• Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood99(1), 36–43 (2002).
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Motta I, Musallam KM, Taher AT. Redefining thalassemia as a hypercoagulable state. Ann. NY Acad. Sci.1202, 231–236 (2010).
   PubMed Web of Science ®Google Scholar
• Vento S, Cainelli F, Cesario F. Infections and thalassaemia. Lancet Infect. Dis.6, 226–233 (2006).
   PubMed Web of Science ®Google Scholar
• Chan GC, Chan S, Ho PL, Ha SY. Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients. Hemoglobin33(5), 352–360 (2009).
   PubMed Web of Science ®Google Scholar
• Hansen K, Singer DB. Asplenic–hyposplenic overwhelming sepsis: postsplenectomy sepsis revisited. Pediatr. Dev. Pathol.4(2), 105–121 (2001).
   PubMed Web of Science ®Google Scholar
• Davies JM, Barnes R, Milligan D. Update of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. Clin. Med.2(5), 440–443 (2002).
   PubMed Web of Science ®Google Scholar
• Origa R, Galanello R, Perseu L et al. Cholelithiasis in thalassemia major. Eur. J. Haematol.82(1), 22–25 (2009).
   PubMed Web of Science ®Google Scholar
• Issaragrisil S, Piankigagum A, Wasi P. Spinal cord compression in thalassemia. Report of 12 cases and recommendations for treatment. Arch. Intern. Med.141(8), 1033–1036 (1981).
   PubMed Web of Science ®Google Scholar
• Cavazzana-Calvo M, Payen E, Negre O et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature467(7313), 318–322 (2010).
   PubMed Web of Science ®Google Scholar
• Pereira AA, Jacobson IM. New and experimental therapies for HCV. Nat. Rev. Gastroenterol. Hepatol.6(7), 403–411 (2009).
   PubMed Web of Science ®Google Scholar
• Angelucci E. Hematopoietic stem cell transplantation in thalassemia. Hematology Am. Soc. Hematol. Educ. Program456–462 (2010).
   PubMed Web of Science ®Google Scholar
• La Nasa G, Argiolu F, Giardini C et al. Unrelated bone marrow transplantation for β-thalassemia patients: the experience of the Italian Bone Marrow Transplant Group. Ann. NY Acad. Sci.1054, 186–189 (2005).
   PubMed Web of Science ®Google Scholar
• Cao A, Rosatelli MC, Galanello R. Control of β-thalassaemia by carrier screening, genetic counselling and prenatal diagnosis: the Sardinian experience. Ciba Found Symp.197, 137–151 (1996).
   PubMedGoogle Scholar